Lu-AG22515 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Lu-AG22515 Growth

1. Differentiated CD40L Mechanism Targeting the Underlying Autoimmune Pathway

Lu AG22515 is a recombinant CD40L/serum albumin fusion protein that blocks the interaction between CD40L and CD40, a key co-stimulatory pathway involved in B-cell activation, autoantibody production, T-cell responses, and inflammatory signaling. Unlike therapies that primarily target downstream inflammatory mediators, CD40L inhibition aims to modulate the upstream autoimmune process driving TED. Lundbeck believes this mechanism could have utility across multiple CD40L-mediated autoimmune diseases beyond TED.

2. Encouraging Early Clinical Efficacy Signals in Thyroid Eye Disease

The ongoing Phase Ib proof-of-concept study has generated encouraging preliminary efficacy data. According to Lundbeck's 2025 investor update, Lu AG22515 demonstrated:

• Proof of mechanism through a clear reduction in anti-TSHR autoantibodies.
• A clinically meaningful reduction in proptosis exceeding 2 mm within a clinically relevant timeframe.
• Early evidence supporting modulation of key pathogenic mechanisms responsible for orbital inflammation and fibrosis in TED.

These findings provide important clinical validation and support advancement into later-stage development.

3. Strong Pharmacodynamic Activity and Favorable Safety Profile

The first-in-human study in healthy volunteers demonstrated that Lu AG22515 was safe and well tolerated across all dose levels. Importantly, investigators observed a robust, sustained, dose-dependent reduction in free soluble CD40L, confirming effective target engagement. This pharmacodynamic evidence substantially de-risks the program by validating the biological mechanism before larger efficacy studies.

4. Significant Unmet Need in Moderate-to-Severe Thyroid Eye Disease

TED remains a debilitating autoimmune disease associated with proptosis, diplopia, pain, inflammation, facial disfigurement, and potential vision loss. Although biologic therapies are available, Lundbeck notes that current treatments are not optimal for all patients and may be associated with tolerability limitations, leaving room for novel immune-modulating therapies. Clinical development is therefore focused on patients requiring additional therapeutic options that directly target autoimmune disease biology.

5. Broad Expansion Potential Across Autoimmune Diseases

One of Lu AG22515's strongest long-term commercial drivers is the broad applicability of CD40L pathway inhibition. Lundbeck has highlighted that CD40-CD40L signaling is involved in numerous autoimmune disorders affecting both adaptive and innate immunity. Positive proof-of-concept in TED could support development in additional autoimmune and neuroimmunological indications, substantially expanding the addressable market beyond a single orphan disease.

Lu-AG22515 Recent Developments

In June 2026, H. Lundbeck A/S (Lundbeck) announced that new data will be presented at the 2026 Endocrine Society's Annual Meeting (ENDO), taking place June 13-16 in Chicago, Illinois, US Lundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in CD, reflecting Lundbeck's expansion into neuroendocrine diseases. In addition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515 in patients with TED will be shared, providing insights into the broader therapeutic potential of CD40L pathway modulation across inflammatory and immunological disorders.

"Lu-AG22515 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Lu-AG22515 for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of Lu-AG22515's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Lu-AG22515 for potential indications. The Lu-AG22515 market report provides insights about Lu-AG22515's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Lu-AG22515 performance, future market assessments inclusive of the Lu-AG22515 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Lu-AG22515 sales forecasts, along with factors driving its market.

Lu-AG22515 Drug Summary

Lu-AG22515 is an investigational anti-CD40 ligand (CD40L) biologic being developed by Lundbeck for the treatment of immune-mediated diseases, including thyroid eye disease (TED) and other neuroimmunological disorders. The molecule is a recombinant bispecific scFv-Fab fusion protein that combines an anti-CD40L single-chain variable fragment with an anti-human serum albumin Fab (SAFA) domain to extend circulating half-life and potentially improve safety. Administered by intravenous infusion, Lu AG22515 inhibits the CD40L/CD40 co-stimulatory pathway, thereby suppressing pathological T-cell and B-cell activation, reducing inflammatory responses, and preserving immune homeostasis without directly depleting immune cells. The drug completed a Phase I first-in-human study in healthy volunteers demonstrating favorable safety, tolerability, pharmacokinetics, and pharmacodynamics, and is currently being evaluated in Phase I clinical trials for moderate-to-severe thyroid eye disease. As of 2026, Lu AG22515 remains an investigational therapy and has not received regulatory approval. The report provides Lu-AG22515's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Lu-AG22515 Market Report

The report provides insights into:

• A comprehensive product overview including the Lu-AG22515 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on Lu-AG22515 regulatory milestones and other development activities have been provided in Lu-AG22515 market report.
• The report also highlights Lu-AG22515's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Lu-AG22515 market report also covers the patents information, generic entry and impact on cost cut.
• The Lu-AG22515 market report contains current and forecasted Lu-AG22515 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Lu-AG22515 market report also features the SWOT analysis with analyst views for Lu-AG22515 in potential indications.

Methodology:

The Lu-AG22515 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lu-AG22515 Analytical Perspective by DelveInsight

• In-depth Lu-AG22515 Market Assessment

This Lu-AG22515 sales market forecast report provides a detailed market assessment of Lu-AG22515 for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Lu-AG22515 sales data uptil 2034.

• Lu-AG22515 Clinical Assessment

The Lu-AG22515 market report provides the clinical trials information of Lu-AG22515 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Lu-AG22515 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Lu-AG22515 Market Potential & Revenue Forecast

• Projected market size for the Lu-AG22515 and its key indications
• Estimated Lu-AG22515 sales potential (Lu-AG22515 peak sales forecasts)
• Lu-AG22515 Pricing strategies and reimbursement landscape

Lu-AG22515 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Lu-AG22515 Market positioning compared to existing treatments
• Lu-AG22515 Strengths & weaknesses relative to competitors

Lu-AG22515 Regulatory & Commercial Milestones

• Lu-AG22515 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Lu-AG22515 Clinical Differentiation

• Lu-AG22515 Efficacy & safety advantages over existing drugs
• Lu-AG22515 Unique selling points

Lu-AG22515 Market Report Highlights

• In the coming years, the Lu-AG22515 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Lu-AG22515 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lu-AG22515's dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to Lu-AG22515 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lu-AG22515 in potential indications.
• Analyse Lu-AG22515 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Lu-AG22515 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Lu-AG22515 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Lu-AG22515? How strong is Lu-AG22515's clinical and commercial performance?
• What is Lu-AG22515's clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lu-AG22515 Manufacturers?
• What are the key designations that have been granted to Lu-AG22515 for potential indications? How are they going to impact Lu-AG22515's penetration in various geographies?
• What is the current and forecasted Lu-AG22515 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Lu-AG22515 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Lu-AG22515 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Lu-AG22515? What is the duration of therapy and what are the geographical variations in cost per patient?